Strategic Leadership in the Age of Digital Disruption

This programme is designed to provide participants with the knowledge tools and capabilities for performance oriented leadership in a globalised business environment operating in an era of perpetual change and digital disruption. It combines three critical and interrelated topics – leadership, change and digital technology and is designed for leaders at all levels of both private and public sector organisations who are responsible for leading technology-enabled change initiatives.

The programme is delivered using an applied blended learning format - a combination of in-class and e-learning, involving online platforms, social media, online apps and the Flipped Classroom. Guest lecturers will complement the student learning and a focus is on peer and team learning.

Key Fact
Who emerges as influential and the leadership practices that best promote organisational effectiveness take on a new meaning when we envision digital technology in the workplace. This exciting new programme provides essential development opportunities as rapid advances in digital technology invites a new genre of leadership.

Subjects taught

Programme Content

Autumn Semester
• The Challenge of Leadership
• Digital Innovation and Transformation

Spring Semester
• Change and Organisational Transformation
• Digital Environmental Audit

Entry requirements

Candidates must have obtained at least an upper Second Class Honours (2:1) Grade or equivalent in an honours BSc in Biotechnology, Biochemistry, Microbiology, Genetics, Neuroscience, Physiology, Pharmacology, Medicinal Chemistry or an equivalent qualification.

If English is not your native language, unless you have done your primary degree through English in an English speaking country, an English language qualification is required for all programmes. English Language qualifications include a minimum score of 550 (213 computer based) for Test of English as a Foreign Language (TOEFL), or 6.5 (with a score of 6 obtained in each category) for International English Language Testing System (IELTS). Other evidence of proficiency in English may be accepted such as the Cambridge Certificate. Tests used as evidence of language proficiency must have been completed within the last 12 months.
2 academic references will be required, at least one to be from a science faculty member.

Students meeting the programme's academic entry requirements but not the English language requirements, may enter the programme upon successful completion of UCD's Pre-Sessional or International Pre-Master's Pathway programmes. Please see the following link for further information

These are the minimum entry requirements – additional criteria may be requested for some programmes.

Application dates

How to apply?
The following entry routes are available:
MSc Biotherapeutics & Business FT (F103)

1 Year

Full Time

Rolling *

* Courses will remain open until such time as all places have been filled, therefore early application is advised.




1 Year Part Time Blended


MSc Biotherapeutics and Business (F103) Full Time
EU fee per year - €13455
nonEU fee per year - €24800

***Fees are subject to change

Tuition fee information is available on the UCD Fees website. Please note that UCD offers a number of graduate scholarships for full-time, self-funding international students, holding an offer of a place on a UCD graduate degree programme. For further information please see International Scholarships.

Enrolment dates

Next Intake: 2020/2021 September

Post Course Info

Careers & Employability
This advanced graduate degree in Biotherapeutics and Business has been developed in consultation with employers and therefore will be recognised and valued by them. A key feature is the opportunity to carry out a business development plan which will allow graduates to develop connections with prospective employers, thereby enhancing chances of employment on graduation.

Prospective employers include: Abbott; Allergan; Amgen; Baxter Healthcare; Eli Lilly and Co.; Dignity Sciences; Glaxo SmithKline; Icon Clinical Research; ImmunoGen Inc.; Janssen Pharmaceutical Ltd.; Johnson & Johnson Ltd.; Merck Sharp & Dohme; Quintiles; Quest International; Sandoz; Seroba Kernel.

More details
  • Qualification letters


  • Qualifications

    Minor Diploma (Level 9 NFQ)

  • Attendance type

    Part time,Blended

  • Apply to

    Course provider